

O 1 5
JUN 29 2005
PATENT & TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/828,795
		Filing Date	April 21, 2004
		First Named Inventor	Weber et al.
		Art Unit	1614
(Multiple sheets used when necessary)		Examiner	Sharon Brooks - Nancy Zhang
SHEET 1 OF 2		Attorney Docket No.	OREX.001A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number <i>Number - Kind Code (if known)</i> Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
3	1	5,512,593	04/30/96	Dante	
3	2	5,817,665	10/06/98	Dante	514/282
3	3	5,856,332	01/05/99	Dante	
3	4	5,958,962	09/28/99	Cook	
3	5	6,034,091	03/07/00	Dante	
3	6	2004/0122033	06/24/04	Nargund et al.	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ¹
3	7	Zhang et al. "Positional cloning of the mouse obese gene and its humane homologue," <i>Nature</i> 372:425-432 (1994).			
3	8	Devlin et al. <i>Int. J. Eating Disord.</i> 28:325-332 (2000).			
3	9	Cone et al. "The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis," <i>Int'l Journal of Obesity</i> , 25(5):S63-S67 (2001).			
3	10	Saper et al. "The need to feed: Homeostatic and hedonic control of eating," <i>Neuron</i> , 36:199-211 (2002).			
3	11	Korner et al. "The emerging science of body weight regulation and its impact on obesity treatment," <i>J. Clin. Invest.</i> , 111(5):565-570 (2003).			
3	12	Portoghesi, P.S. <i>J. Med. Chem.</i> , 35:1927 (1992).			
3	13	Carroll, F.I. <i>J. Med. Chem.</i> , 46:10 (2003).			
3	14	Glass et al. <i>Neuropeptides</i> , 33:350 (1999).			
3	15	Schmidhammer et al. <i>A. Helv. Chim. Acta</i> , 77:999 (1994).			
3	16	Hahn et al. "J. Pharm. Exper. Therapeutics", 235:846-850 (1985).			
3	17	Kolb et al. <i>A. Pharmaceutical Res.</i> , 6:266-271 (1985).			
3	18	Pasternak et al. <i>J. of Med. Chem.</i> , 23:674-676 (1980).			

Examiner Signature <i>Nancy Zhang</i>	Date Considered <i>8/16/06</i>
---------------------------------------	--------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/828,795
		Filing Date	April 21, 2004
		First Named Inventor	Weber et al.
		Art Unit	1614
(Multiple sheets used when necessary)		Examiner	Sharon Brooks <i>Nancy Zhang</i>
SHEET 2 OF 2		Attorney Docket No.	OREX.001A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>z</i>	19	Le Bourdonnec et al. <i>J. Med. Chem.</i> , 43:2489-2492 (2000).	
<i>z</i>	20	Sayre et al. <i>J. Med. Chem.</i> , 27:1325 (1984).	
<i>z</i>	21	Erez et al. <i>J. Med. Chem.</i> , 25:847-849 (1982).	
<i>z</i>	22	Dechant et al. <i>Drugs</i> , 41:225-253 (1991).	
<i>z</i>	23	Tamiz et al. <i>J. Am. Chem. Soc.</i> , 122:5393-5394 (2000).	
<i>z</i>	24	Tamiz et al. <i>J. Med. Chem.</i> , 44:1615-1622 (2001).	
<i>z</i>	25	Hussey et al. <i>J. Am. Chem. Soc.</i> , 125:3692-3693 (2003).	
<i>z</i>	26	Portoghese et al. <i>Life Sci.</i> , 31:1283-1286 (1982).	
<i>z</i>	27	Portoghese et al. <i>J. Med. Chem.</i> , 29:1855-1861 (1986).	
<i>z</i>	28	Stepinski et al. <i>Internat. J. of Peptide & Protein Res.</i> , 38:588-592 (1991).	
<i>z</i>	29	Parr et al. <i>J. Immunol.</i> , 169:856-864 (2002).	
<i>z</i>	30	Klok et al. <i>Macromolecules</i> , 35:746-759 (2002).	
<i>z</i>	31	Portoghese et al. <i>J. Med. Chem.</i> , 29:1650-1653 (1986).	
<i>z</i>	32	Sashiwa et al. <i>Macromolecules</i> , 33:6913 (2000).	
<i>z</i>	33	Ninan et al. <i>Tetrahedron</i> , 48:6709:16 (1992).	
<i>z</i>	34	Zeng et al. <i>Tetrahedron Lett.</i> , 29:5123 (1988).	
<i>z</i>	35	Remington's <i>Pharmaceutical Sciences</i> . 18 th Edition; Easton, PA: Mack Publishing Co. (1990).	
<i>z</i>	36	Fingl et al. <i>The Pharmacological Basis of Therapeutics</i> . Ch.1, pp 1. (1975).	


1787941
062405

Examiner Signature <i>Nancy Zhang</i>	Date Considered <i>8/16/06</i>
---------------------------------------	--------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/828,795
		Filing Date	April 21, 2004
		First Named Inventor	Eckard Weber
		Art Unit	1614
OIP (Multiple sheets used when necessary)		Examiner	Sharon Brooks Nancy Zhang
SHEET 1 OF 1		Attorney Docket No.	OREX.001A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>NZ</i>	1	Spigset, et al. <i>Therapeutic Approaches to Bulimia Nervosa, Expert Opinion on Therapeutic Patents</i> , Vol. 11, No. 3, 2001, Pages 463-477; XP002292382	
<i>NZ</i>	2	Islam, et al. <i>Naltrexone, Serotonin Receptor Subtype Antagonists, and Carbohydrate Intake in Rats, Pharmacology Biochemistry and Behavior</i> , Vol. 48, No. 1, 1994, pages 193-201; XP002292383	
<i>NZ</i>	3	Olszewski, et al. <i>Evidence of Interactions Between Melanocortin and Opioid Systems in Regulation of Feeding, Neuroreport</i> , Vol 12, No. 8, June 13, 2001, pages 1727-1730; XP009035026.	
<i>NZ</i>	4	Zhu, et al. <i>Pharmacologic Treatment of Eating Disorders, Canadian Journal of Psychiatry</i> , Vol 47 No. 3, April 3, 2002 pages 227-234; XP009035028	
<i>NZ</i>	5	Werneke, et al. <i>Options for Pharmacological Management of Obesity in patients Treated with Atypical Antipsychotics, International Clinical Psychopharmacology</i> , Vol 17 No. 4, 2002, pages 145-160; XP009035036	
<i>NZ</i>	6	Fuller et al., <i>Fluoxetine: A Serotonergic Appetite Suppressant Drug, Drug Development Research</i> , Vol. 17, No. 1, 1989, pages 1-15; XP009035038.	
<i>NZ</i>	7	International Preliminary Examination Report PCT Application PCT/US2004/012393, mailed on June 29, 2005.	

1906871
083105

Examiner Signature <i>Nancy Zhang</i>	Date Considered <i>8/16/06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

^{T¹} - Place a check mark in this area when an English language Translation is attached.